title: Equivalence between pre-exposure schemes for human rabies and evaluation of the need for serological monitoring.
abstract: OBJECTIVE
  To evaluate the humoral immune response to the pre-exposure schedule of human rabies vaccination through intradermal and intramuscular routes, as well as the need for serological monitoring.
  
  
  METHODS
  A randomized and controlled intervention study was carried out in São Paulo, Southeastern Brazil, from 2004-2005. There were 149 volunteers, of which 127 completed the vaccination schedule (65 intradermal and 62 intramuscular) and underwent humoral immune response evaluation at ten, 90 and 180 days post-vaccination. Two outcomes were considered for comparing the two routes of administration: the geometric average of neutralizing antibody titers and the proportion of individuals with satisfactory titers (> 0.5 IU/mL) at each evaluation point. The association of the humoral immune response with anthropometric and demographic data was analyzed through a normal distribution test and a chi-square test with a Yates correction. After completion of the vaccination schedule, the proportion of seropositive results was compared by the Kruskall Wallis test, and the average titers were compared by variance analysis.
  
  
  RESULTS
  the average antibody titers were higher in patients who were vaccinated intramuscularly. The percentage of volunteers with satisfactory titers (> 0.5% IU/mL) decreased over time in both groups. However, in the group vaccinated intradermally the rate of satisfactory titers on day 180 ranged from 20% to 25%, while the intramuscular route varied from 63% to 65%. An association between the humoral immune response and the demographic and anthropometric variables was not observed.
  
  
  CONCLUSIONS
  Serology after the third dose can be considered unnecessary in unexposed patients, since 97% and 100% of volunteers respectively vaccinated by the intradermal and intramuscular route presented satisfactory antibody levels (> 0.5% IU/mL).
authors.affiliation: Instituto Pasteur, São Paulo, SP, Brazil. siqueira89@hotmail.com <siqueira89@hotmail.com>
authors.forename: Ricardo Siqueira
authors.initials: RS
authors.lastname: Cunha
authors.forename: Andréa de Cássia Rodrigues da
authors.initials: Ade C
authors.lastname: Silva
authors.forename: Alexandre Mendes
authors.initials: AM
authors.lastname: Batista
authors.forename: Luciana Botelho
authors.initials: LB
authors.lastname: Chaves
authors.forename: Rita Barradas
authors.initials: RB
authors.lastname: Barata
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000276:immunology*; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D008297:Male; D011818:Rabies / Q000517:prevention & control; D011819:Rabies Vaccines / Q000008:administration & dosage* / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D011819:Rabies Vaccines